Evidence map›Paper›PMID 40455297›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025

Cutaneous adverse effects of combination epidermal growth factor receptor inhibitor and immune checkpoint inhibitor cancer therapy.

Ishani P Kale, Erika M McCauley, Anisha B Patel

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ishani P Kale *University of Texas McGovern Medical School, Houston, TX, USA.
Erika M McCauley *University of Texas McGovern Medical School, Houston, TX, USA.
Anisha B PatelUniversity of Texas McGovern Medical School, Houston, TX, USA. APatel11@mdanderson.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeEpidermal growth factor receptor inhibitors (EGFRIs) and immune checkpoint inhibitors (ICIs) show promising efficacy in colorectal cancer and head and neck squamous cell carcinoma therapy, especially in combination. However, given the many cutaneous adverse effects (CAE) associated with each, there is concern for overlap and exacerbation of toxicities. EGFRIs are associated with acneiform rashes and paronychia, while ICIs are associated with lichenoid dermatitis and psoriasis. Xerosis, pruritus, and eczema are seen with both drugs. Understanding the CAEs of EGFRI-ICI combination therapy may guide the management of toxicities and improve adherence to life-saving therapy.

methodsA retrospective chart review of patients treated with EGFRI/ICI combination between January 1, 2015, and May 21, 2024, was performed. Data on demographics, cancer type, and CAE incidence, duration, and management were manually investigated.

resultsForty-four patients were identified on EGFRI/ICI therapy, with 26 patients (59%) developing a total of 42 CAEs. Patients received cetuximab-pembrolizumab (72%) or cetuximab-nivolumab (28%) therapy. The most common CAEs seen were acneiform eruption (33%) and eczema (18%). Most CAEs were caused by EGFRI (62%) with 12% attributable to ICI, and 24% of CAEs attributed to either/both drugs. Most CAEs were reported as mild to moderate.

conclusionCombination EGFRI/ICI therapy is quickly becoming standard treatment in certain cancers, and the incidence of CAEs is high (59%) in this population. CAEs appear to be skewed towards EGFRI rashes and low-grade severity. A prospective trial is warranted to further understand the impact of CAEs for patients being treated with this combination therapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsDrug EruptionsImmune Checkpoint InhibitorsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedCetuximabColorectal NeoplasmsErbB ReceptorsFemaleHead and Neck NeoplasmsHumansMaleMiddle AgedRetrospective StudiesAntibodies, Monoclonal, HumanizedCetuximabErbB ReceptorsImmune Checkpoint InhibitorspembrolizumabAdverse effectsCancer therapyEGFRI/ICIEpidermal growth factor receptor inhibitorImmune checkpoint inhibitor

Identifiers

PMID40455297

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.